A patient sat across from me last spring, lifting the hem of her shirt the way so many do in that first consult — half apology, half hope. She’d lost sixty pounds on semaglutide over the better part of a year. “I did the hard part,” she said. “I just can’t fix this last piece on my own.” She was right. No amount of planks was going to retighten skin that had been stretched and then deflated. That’s a surgical problem, and it’s one I’ve spent more than two decades solving.
What struck me wasn’t her story — I hear a version of it every week now. It was her skin. Her labs. The way her tissue handled in the operating room a few weeks later. After thousands of body contouring cases, I’ve developed a feel for which patients are going to sail through and which ones are going to test every suture I place. And the patients walking in off GLP-1 medications keep surprising me, in a good way.
I wanted to know if my gut was telling me something real, so I went looking for the data. A comparative study published this June in Plastic and Reconstructive Surgery — the flagship journal in my field — asked exactly the question I’d been turning over in the OR.
What the study actually looked at
For years, “massive weight loss patient” meant one thing in my world: someone who’d had bariatric surgery. Gastric bypass, sleeve gastrectomy. These are wonderful operations that have changed lives, but from a plastic surgeon’s chair, they hand us a more complicated patient. Now there’s a second road to dramatic weight loss, and it’s getting crowded — by 2024, roughly one in eight American adults had used a GLP-1 medication. A lot of them are going to end up in a consult room like mine.
So the question is straightforward: when these patients come to us for a tummy tuck, do they do as well as the bariatric patients we’ve spent decades learning to operate on? Better? Worse?
The researchers — Friedman and Tal — compared forty abdominoplasty patients — twenty who lost their weight on semaglutide or tirzepatide, twenty who lost it through bariatric surgery — matched closely for age, sex, and their weight at the time of surgery. Same surgical technique on every case. Same drains, same progressive tension sutures, same protocols. Then they tracked complications and satisfaction out to a full year.
What the numbers showed
The GLP-1 patients had complications about half as often: 20 percent versus 40 percent in the bariatric group. Major complications — the kind that send you back to the OR or onto IV antibiotics — ran 5 percent versus 20 percent.
Now, I have to be honest with you the same way I’d be honest with a patient about a result that looks great but needs a caveat. With only twenty patients in each group, those differences didn’t cross the line into statistical significance. Forty patients is a small study. What it found is a trend, a strong and consistent one, pointing in a direction that matches everything I see with my own hands. It’s the difference between “this is proven” and “this is real and we need a bigger study to nail it down.” I’d be doing you a disservice to oversell it.
But two things weren’t subtle at all.
First, nutrition. The GLP-1 patients walked into surgery with meaningfully better protein stores — higher albumin, higher prealbumin. That matters more than most people realize. Protein is the raw material your body uses to build a healed incision. When I operate on a depleted patient, I’m asking the tissue to do construction work without enough lumber. The bariatric patients, with their rerouted or restricted anatomy, simply absorb less of what they eat. The GLP-1 patients have a completely normal gut. They just eat less. Their plumbing works fine, and it shows in their labs.
Second, satisfaction. At one year, the GLP-1 group rated their experience 8.6 out of 10 versus 7.6. Every single patient in both groups — all forty — said they’d do it again. That tells me the operation is worth it across the board. But the gap is interesting, and I have a theory about it.
Why I think these patients heal differently
Three things stand out to me, and they line up with what I notice case to case.
The skin behaves differently. Bariatric patients often lose enormous amounts of weight fast — I had one gentleman who dropped over a hundred pounds in his first year after a bypass. Spectacular for his health, but his skin had whiplash. The GLP-1 patients lose weight more gradually, often over a year to eighteen months. Skin is a living organ, and it responds to a slower process by holding onto more of its elasticity and its blood supply. When I’m lifting and redraping that tissue, the difference is tangible.
There’s no prior abdominal surgery. Almost none of my GLP-1 patients have ever had their belly operated on. The bariatric patients all carry laparoscopic port scars, and underneath, often a layer of adhesions and a compromised abdominal wall blood supply. Those old incisions are weak points, and I have to respect them. With a GLP-1 patient, I’m usually working on a clean, never-touched abdomen. That’s a gift.
And the nutrition piece again, because it’s that important. A well-fed patient heals. I’ve watched it for twenty-five years.
What this does NOT mean
Here’s where I have to put on the brakes, because the headlines on this topic tend to run wild.
A 20 percent complication rate is still a 20 percent complication rate. My cosmetic tummy tuck patients — the ones who never gained the weight in the first place — run more like 1 to 5 percent. So even the “easier” weight-loss patient is a higher-risk operation than a standard tummy tuck. If you’ve lost a lot of weight and you’re considering body contouring, you are not a routine cosmetic case, and any surgeon who treats you like one is cutting corners.
That means we do the work up front. We optimize your protein for weeks before surgery. We manage your GLP-1 medication carefully around your anesthesia — these drugs slow your stomach down and raise aspiration risk, so we hold them for a week before your operation and restart once you’re eating normally again, usually around two weeks out. We use every technique that drives complication rates down: progressive tension sutures, careful drain management, the conservative principles I learned operating on the hardest weight-loss cases. I’m not loosening my standards for these patients just because their labs look good. I’m bringing the same rigor — they just tend to reward it more.
One more honest note: we don’t yet know what happens long-term if someone stops their GLP-1 medication and regains weight. Roughly a third of people come off these drugs eventually, often over cost or side effects. Your surgical result is built for the body you have on the day of surgery. If that body changes significantly, the result can change too. That’s a real conversation I have with every patient before we schedule.
Where this leaves us
We’re at the front edge of something. These medications are reshaping who walks into plastic surgery offices, and the field is scrambling to catch up. This kind of study is a small, early look — nobody should treat it as the final word. We need multicenter trials with hundreds of patients and longer follow-up before anyone declares victory.
But I’ll tell you what I told that patient last spring, after her one-week check when everything looked beautiful: the work she did to lose the weight set her up for the best possible result. The hard part really was behind her. My job was just to honor it.
If you’ve lost significant weight — however you got there — and you’re wondering what comes next for the skin that’s left, I’d be glad to talk it through. Bring your questions. Bring the half-apology, half-hope. I’ve seen it before, and I know what to do with it.
Dr. Michael Spann is a double board-certified plastic and reconstructive surgeon practicing in Little Rock, Arkansas. This article reflects clinical observations and published findings and is not medical advice; individual candidacy for surgery is determined during an in-person consultation.
